Galmed Pharmaceuticals Stock Market Value
| GLMD Stock | USD 0.67 0.01 1.47% |
| Symbol | Galmed |
Will Biotechnology sector continue expanding? Could Galmed diversify its offerings? Factors like these will boost the valuation of Galmed Pharmaceuticals. Market participants price Galmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galmed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Galmed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Galmed's balance sheet. Smart investors calculate Galmed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Galmed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Galmed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Galmed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Galmed Pharmaceuticals.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Galmed Pharmaceuticals on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Galmed Pharmaceuticals or generate 0.0% return on investment in Galmed Pharmaceuticals over 90 days. Galmed Pharmaceuticals is related to or competes with Biovie, Theriva Biologics, Moolec Science, Chemomab Therapeutics, InMed Pharmaceuticals, Biodexa Pharmaceticals, and Virax Biolabs. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Galmed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Galmed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Galmed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 21.39 | |||
| Value At Risk | (8.62) | |||
| Potential Upside | 9.33 |
Galmed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galmed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Galmed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Galmed Pharmaceuticals historical prices to predict the future Galmed Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.41) | |||
| Treynor Ratio | (0.67) |
Galmed Pharmaceuticals February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.66) | |||
| Mean Deviation | 4.05 | |||
| Coefficient Of Variation | (683.75) | |||
| Standard Deviation | 5.31 | |||
| Variance | 28.2 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.41) | |||
| Treynor Ratio | (0.67) | |||
| Maximum Drawdown | 21.39 | |||
| Value At Risk | (8.62) | |||
| Potential Upside | 9.33 | |||
| Skewness | 0.1788 | |||
| Kurtosis | 0.4787 |
Galmed Pharmaceuticals Backtested Returns
Galmed Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.11, which attests that the entity had a -0.11 % return per unit of risk over the last 3 months. Galmed Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Galmed Pharmaceuticals' Standard Deviation of 5.31, market risk adjusted performance of (0.66), and Risk Adjusted Performance of (0.11) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.18, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Galmed Pharmaceuticals will likely underperform. At this point, Galmed Pharmaceuticals has a negative expected return of -0.58%. Please make sure to check out Galmed Pharmaceuticals' jensen alpha and the relationship between the potential upside and day median price , to decide if Galmed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.33 |
Below average predictability
Galmed Pharmaceuticals has below average predictability. Overlapping area represents the amount of predictability between Galmed Pharmaceuticals time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Galmed Pharmaceuticals price movement. The serial correlation of 0.33 indicates that nearly 33.0% of current Galmed Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.33 | |
| Spearman Rank Test | 0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Galmed Pharmaceuticals Correlation, Galmed Pharmaceuticals Volatility and Galmed Pharmaceuticals Performance module to complement your research on Galmed Pharmaceuticals. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Galmed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.